Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorIndiana University
About this trial
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Diagnosis of ocular hypertension or open-angle glaucoma
Eye examination within the past year
For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma
Disqualifiers
Known intolerance to netarsudil ophthalmic solution
Corneal scarring or active corneal disease that would interfere with imaging
Inability to tolerate gonioscopy procedures
Females of childbearing potential who are not using effective contraception or are not sterile
Trial design
Treatments tested in this trial
- Netarsudil Ophthalmic Solution (Rhopressa)
- Artificial Tears (AT)
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Indiana University
Lead sponsor
Alcon Research
Collaborator
Source ClinicalTrials.gov